RedChip Companies

RedChip is the world leader in investor relations, financial media, and research for microcap and small-cap stocks. RedChip has helped hundreds of companies achieve their capital markets goals and has been ranked by Inc. Magazine as one of the fastest growing privately held investor relations firms in the U.S. #finance #capitalmarkets #investorrelations

📣 Venu Holding Corporation (NYSE American: VENU) Investor Webinar Set for April 21 Mark your calendars: VENU is hosting an investor webinar on Monday, April 21 at 4:15 PM ET, offering key insights into the company’s strategic growth and upcoming developments. 🎯 Why This Matters to Investors: - Expansion Momentum: VENU recently announced the acquisition of a high-traffic site in Centennial, Colorado—part of its multi-market rollout of upscale indoor music venues featuring Luxe FireSuites and exclusive fractional ownership options. - Innovative Business Model: With hospitality-driven venues like The Hall at Bourbon Brothers and partnerships with major players like AEG Presents and Troy Aikman, VENU is reshaping the premium entertainment landscape. - Growth Markets: Active in Colorado, Georgia, and soon Texas and Oklahoma, VENU is tapping into fast-growing regional economies with strong consumer demand for elevated live entertainment experiences. 🔗 Join the webinar to learn more about VENU's expansion plans and investor-focused strategy: https://lnkd.in/d3RHCFrf VenuesNow Real Estate EIGHT Elite Light Lager #RedChip #RedChat #VENU #LiveEntertainment #RevenueGrowth #Investing #SmallCapStocks #Hospitality

China halts critical rare earth mineral exports as Trump teases new tariffs. Nova Minerals Limited (Nasdaq: NVA) developing a ~9.9M/Oz gold + antimony asset in America's next major critical minerals district. 🖇️ https://lnkd.in/edGv5PXC #NovaMinerals #RedChipClient #RedChat #preciousmetals #antimony #Alaska #goldrush #Gold #MiningStocks

🧠 Nexalin Technology (Nasdaq: NXL) Granted US Patent for Drug-Free Brain Stimulation in Addiction Treatment Nexalin Technology has been granted a U.S. patent for its Deep Intracranial Frequency Stimulation (DIFS™) tech—a non-invasive solution targeting opioid, alcohol, and stimulant use disorders. 💡 Why This Matters for Investors: ✅ Strengthens IP Portfolio: New patent reinforces Nexalin Technology's leadership in neuromodulation for addiction treatment. ✅ High-Impact Market: Substance use disorders affect millions globally—Nexalin's drug-free alternative offers a scalable path to recovery. ✅ Strategic Edge: DIFS™ targets neural circuits tied to cravings, anxiety, and depression—key relapse drivers—positioning Nexalin Technology at the forefront of brain-based therapies. 🔗 https://lnkd.in/ekb249Gc Neuroscience News Neuroscience Biotechnology #Nexalin #RedChip #RedChat #Biotech #MentalHealth #PTSD #FinancialNews #Investing

📢 Connect Biopharma (Nasdaq: CNTB) Hosts Investor Webinar Tomorrow at 4:15 PM ET Connect Biopharma invites investors to its upcoming webinar to discuss corporate strategy and pipeline priorities—including next steps for rademikibart in acute asthma and COPD care. 💡 Why This Matters to Investors: - With FDA alignment now secured, Connect Biopharma is preparing to launch two parallel Phase 2 trials in Q2 2025 targeting a massive unmet need—acute exacerbations of asthma and COPD. This area impacts over 2.3 million patients annually in the U.S. alone and currently has no approved biologics. With promising early efficacy and a clear clinical roadmap, Connect Biopharma is one to watch heading into mid-2025. 🔗 https://lnkd.in/etbYgKku Biotechnology Biotechnology, Biomedicine and Bioengineering #CNTB #Asthma #COPD #Biotech #ClinicalTrials #RespiratoryCare #Investing #finance

💰 Can-Fite (NYSE American: CANF) $685M in Potential Revenue from Global Partnerships Can Fite BioPharma (CANFY) projects up to $685.9M in future revenue from its collaborations for lead drug candidates Piclidenoson and Namodenoson, based on milestones, royalties, and licensing terms. 🌍 7 Partners Across Key Markets 📈 Indications: Psoriasis, Liver & Pancreatic Cancer, MASH 📅 Forecasted launches: 2027–2029 (pending approvals) 🔬 Backed by global licensing, Can-Fite's pipeline of Phase III assets are positioned for significant long-term value. 📄 Full Release: https://lnkd.in/ej_jHYZH Biotechnology Biotech Network #RedChip #RedChat #CANF #Biotech #LicensingDeals #DrugDevelopment #Oncology #MASH #Psoriasis #BiotechInvesting #RevenueGrowth

🚨 Gorilla Technology (Nasdaq: GRRR) Confirms $4.5M+ in Buybacks To-Date as AI Veteran Joins Americas Expansion Gorilla Technology Group has repurchased over $4.5M in stock under its $10M buyback plan—signaling confidence in long-term value. Gorilla also announced further strengthening of its team with appointment of AI leader Satish Venkatesan as Chief Solutions Strategist – Americas. 💡 Why It Matters 🔹 Buybacks reinforce management’s conviction in Gorilla Technology Group's intrinsic value 🔹 Venkatesan brings 30+ years’ experience, incl. $100M+ digital portfolios at Cognizant 🔹 He’ll lead U.S. & LATAM strategy, incl. the Amazon Smart Corridor 📄 Full Release: https://lnkd.in/ejhMHXTk #RedChip #RedChat #SmartGrid #AI #SaaS #SmartWarehousing #Thailand #TechInvesting #Infrastructure

🚨 FDA’s New Policy Paves the Way for BullFrog AI's (Nasdaq: BFRG) Breakthrough Platform 📢 The FDA announced it will phase out mandatory animal testing for monoclonal antibodies and other drugs, embracing AI-based models and human-derived testing systems instead. This shift aligns directly with BullFrog AI's mission and capabilities. 🔍 Why This Matters for Investors: ✅ Regulatory Tailwind: FDA’s move validates AI-powered platforms like BullFrog Data Networks® and bfLEAP®—which analyze complex, high-dimensional datasets to predict drug safety and efficacy with human relevance. ✅ Cost & Time Savings: By reducing reliance on animal trials, BullFrog’s AI can help partners cut R&D timelines and costs—key to competing in today’s capital-constrained environment. ✅ Market Alignment: BullFrog AI's focus on supporting small-to-mid-sized biopharma with affordable, scalable AI tools positions it to benefit from an industry-wide push toward non-animal, human-centric drug development. BullFrog AI is uniquely positioned to capitalize on this regulatory shift, with a platform built to accelerate safer, smarter drug development. 📄 Learn more about BullFrog AI: https://lnkd.in/e9zVpH53 Vin Singh Lieber Institute for Brain Development Biotechnology Studies at Johns Hopkins AAP Biotechnology #BullfrogAI #RedChip #RedChat #AI #BiotechStocks #BFRG #DrugDiscovery #Nasdaq #Innovation #Investing

🛡️ FatPipe (Nasdaq: FATN) Unveils Total Security 360 – Simplifying Cybersecurity for SMBs FatPipe Networks launches its Total Security 360 platform: an all-in-one solution combining SD-WAN, NextGen Firewall, and cybersecurity tools into a single, easy-to-deploy stack designed for small and mid-sized businesses. 💡 Why This Matters for Investors: - SMB Market Focus: Targets the underserved small-to-mid business segment with a cost-effective, comprehensive cybersecurity solution. - Operational Efficiency: Single-pane-of-glass management streamlines monitoring and improves threat detection. - Insurance Impact: Simplified cybersecurity stack may reduce insurance premiums for customers—an added value driver. With 12 U.S. patents and a global reseller network, FatPipe Networks is positioned as a go-to provider for secure, scalable network solutions in a high-growth market. 🔗 https://lnkd.in/gtdGD6Ke SDWAN and SASE Solutions Prisma SASE by Palo Alto Networks #IPO #TechStocks #Cybersecurity #NetworkingSolutions #Investing #FinancialNews

🚨 ConnectM (Nasdaq: CNTM): Buyout Group Reaffirms $1.60/Share Offer, Now Valued at $62M ConnectM Technology Solutions confirmed that its updated share count brings the total equity value of the pending $1.60/share go-private offer to $62.02M, up from the previously estimated $46.5M. The investor group remains committed to moving forward. 💼 Why It Matters • Valuation clarity improves deal transparency • Buyer commitment reaffirmed despite higher implied cost • ThinkEquity engaged to support strategic review 📄 Full Release: https://lnkd.in/ezjz9qpX GE Vernova Electrification Coalition S&P Global Commodity Insights #CNTM #AI #Electrification #EV #Investing #EnergyTransition #StockMarket